Plain-English translation of NCT06375915 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new combination approach for a difficult-to-treat bile duct cancer called intrahepatic cholangiocarcinoma. The study combines three types of treatment: a specialized radiation technique called radioembolization, standard chemotherapy drugs ( and ), and an immune-boosting medication called that helps your body's immune system fight cancer. The goal is to see if using these treatments together can work better than current standard treatments for people whose cancer cannot be removed by surgery.
Bile duct cancer is aggressive and often returns quickly after treatment. Many patients do not respond well to current standard treatments. By combining local radiation with systemic (body-wide) chemotherapy and a medication that activates the immune system, researchers hope to create a stronger anti-cancer effect that may help more patients benefit and live longer.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive the combination treatment as the single study arm—meaning all participants receive the same approach. This involves undergoing radioembolization (a minimally invasive procedure using radioactive microspheres delivered to the tumor), followed by chemotherapy infusions and the immune-boosting medication, given over several weeks. You will attend regular clinic visits for blood tests, imaging scans, and medical evaluations to monitor how well the treatment is working and to track any side effects. The study is expected to enroll about 33 patients across multiple medical centers.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
Italy